These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 1912105)

  • 1. A pilot placebo-controlled study of chronic m-CPP administration in Alzheimer's disease.
    Lawlor BA; Sunderland T; Mellow AM; Molchan SE; Martinez R; Murphy DL
    Biol Psychiatry; 1991 Jul; 30(2):140-4. PubMed ID: 1912105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A preliminary study of the effects of intravenous m-chlorophenylpiperazine, a serotonin agonist, in elderly subjects.
    Lawlor BA; Sunderland T; Mellow AM; Hill JL; Newhouse PA; Murphy DL
    Biol Psychiatry; 1989 Mar; 25(6):679-86. PubMed ID: 2923931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavioral effects of trazodone in Alzheimer's disease.
    Lebert F; Pasquier F; Petit H
    J Clin Psychiatry; 1994 Dec; 55(12):536-8. PubMed ID: 7814348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of daily oral m-chlorophenylpiperazine in elderly depressed patients. Initial experience with a serotonin agonist.
    Mellow AM; Lawlor BA; Sunderland T; Mueller EA; Molchan SE; Murphy DL
    Biol Psychiatry; 1990 Oct; 28(7):588-94. PubMed ID: 2223928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A preliminary study of the effects of nighttime administration of the serotonin agonist, m-CPP, on sleep architecture and behavior in healthy volunteers.
    Lawlor BA; Newhouse PA; Balkin TJ; Molchan SE; Mellow AM; Murphy DL; Sunderland T
    Biol Psychiatry; 1991 Feb; 29(3):281-6. PubMed ID: 2015332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroendocrine effects of M-chlorophenylpiperazine, a serotonin agonist, in humans.
    Mueller EA; Murphy DL; Sunderland T
    J Clin Endocrinol Metab; 1985 Dec; 61(6):1179-84. PubMed ID: 4055985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daily administration of m-chlorophenylpiperazine to healthy human volunteers rapidly attenuates many of its behavioral, hormonal, cardiovascular and temperature effects.
    Benjamin J; Greenberg BD; Murphy DL
    Psychopharmacology (Berl); 1996 Sep; 127(2):140-9. PubMed ID: 8888380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder.
    Pigott TA; Zohar J; Hill JL; Bernstein SE; Grover GN; Zohar-Kadouch RC; Murphy DL
    Biol Psychiatry; 1991 Mar; 29(5):418-26. PubMed ID: 2018816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trazodone and its active metabolite m-chlorophenylpiperazine as partial agonists at 5-HT1A receptors assessed by [35S]GTPgammaS binding.
    Odagaki Y; Toyoshima R; Yamauchi T
    J Psychopharmacol; 2005 May; 19(3):235-41. PubMed ID: 15888508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind, placebo-controlled crossover study of ganglioside GM1 treatment for Alzheimer's disease.
    Flicker C; Ferris SH; Kalkstein D; Serby M
    Am J Psychiatry; 1994 Jan; 151(1):126-9. PubMed ID: 8267111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine's anxiogenic effects.
    Klein E; Zohar J; Geraci MF; Murphy DL; Uhde TW
    Biol Psychiatry; 1991 Nov; 30(10):973-84. PubMed ID: 1756202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.
    Florian H; Meier A; Gauthier S; Lipschitz S; Lin Y; Tang Q; Othman AA; Robieson WZ; Gault LM
    J Alzheimers Dis; 2016; 51(4):1237-47. PubMed ID: 26967214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot study of serotonergic system responsivity in Alzheimer's disease.
    Lawlor BA; Mellow AM; Sunderland T; Hill JL; Murphy DL
    Psychopharmacol Bull; 1988; 24(1):127-9. PubMed ID: 3290935
    [No Abstract]   [Full Text] [Related]  

  • 14. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.
    Alvarez XA; Mouzo R; Pichel V; Pérez P; Laredo M; Fernández-Novoa L; Corzo L; Zas R; Alcaraz M; Secades JJ; Lozano R; Cacabelos R
    Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):633-44. PubMed ID: 10669911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperresponsivity to the serotonin agonist m-chlorophenylpiperazine in Alzheimer's disease. A controlled study.
    Lawlor BA; Sunderland T; Mellow AM; Hill JL; Molchan SE; Murphy DL
    Arch Gen Psychiatry; 1989 Jun; 46(6):542-9. PubMed ID: 2730278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.
    Rogers SL; Doody RS; Mohs RC; Friedhoff LT
    Arch Intern Med; 1998 May; 158(9):1021-31. PubMed ID: 9588436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease.
    Cummings JL; Schneider L; Tariot PN; Kershaw PR; Yuan W
    Am J Psychiatry; 2004 Mar; 161(3):532-8. PubMed ID: 14992980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GM-1 treatment of Alzheimer's disease. A pilot study of safety and efficacy.
    Ala T; Romero S; Knight F; Feldt K; Frey WH
    Arch Neurol; 1990 Oct; 47(10):1126-30. PubMed ID: 2222246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease.
    Streim JE; Porsteinsson AP; Breder CD; Swanink R; Marcus R; McQuade R; Carson WH
    Am J Geriatr Psychiatry; 2008 Jul; 16(7):537-50. PubMed ID: 18591574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic treatment with meta-chlorophenylpiperazine (m-CPP) alters behavioral and cerebral metabolic responses to the serotonin agonists m-CPP and quipazine but not 8-hydroxy-2(di-N-propylamino)tetralin.
    Freo U; Holloway HW; Greig NH; Soncrant TT
    Psychopharmacology (Berl); 1992; 107(1):30-8. PubMed ID: 1534179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.